SEC Form 4 · accession 0001387131-16-004943
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Scott Slakter
Officer — Chief Executive Officer · Director
Period of report
Apr 11, 2016
Accepted (ET)
Apr 12, 2016 · 1:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share | Apr 11, 2016 | P | 6,250 | $3.35 | A | 884,504 | D | |
| Common Stock, par value $0.0001 per shareF1 | holding | — | — | — | 697,865 | I | By SKS Ocular I LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1SKS Ocular I LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular I LLC. Pursuant to the acquisition agreement, among other things, SKS Ocular I LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestone 1 has been met and on December 15, 2015, the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC. The Reporting Person has investment and voting power with respect to the Common Stock held by SKS Ocular I LLC. Therefore, the reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular I LLC. The Reporting Person disclaims any beneficial ownership of the Common Stock directly owed by SKS Ocular I LLC except to the extent of his pecuniary interest therein.